SLRX Dhuwit awis perusahaan Salarius Pharmaceuticals

Simbol resmi perusahaan Salarius Pharma (SLRX)

The development of Salarius Pharmaceuticals (SLRX) is independent of macroeconomic trends, relying instead on the results of targeted drug trials. Strategic alliances with oncology centers enhance its scientific potential and attractiveness for acquisitions. The level of cash reserves reflects the capital dynamics, with the current level standing at 0.01. Business stability is determined by external investments and the success of R&D, as the company lacks a regular cash flow.

Aset likuid perusahaan: Salarius Pharma (SLRX) kanggo 04.07.2022 - 08.01.2026

Salarius Pharmaceuticals, Inc. - rincian analitis lan metrik utama (SLRX)

Pambiji fundamental:Salarius Pharma
Produk mawa merek salariuspharma.com

Efficient clinical trial logistics for Salarius Pharmaceuticals (SLRX) correlate with the company's cash dynamics. This indicator aggregates all highly liquid assets, determining the volume of reserves available to cover operating expenses. The metric allows for an assessment of the business's financial autonomy in the event of a sharp decline in revenue. For oncology drugs, such reserves are critical for maintaining temperature-controlled supply chains. Investors should seek a balance between solvency and excess capital.

Analisis perusahaan pesaing

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Cadangan dhuwit perusahaan|SELLAS Life Sciences Group - Volume dana dhuwit perusahaan|ACTU - Volume dana dhuwit perusahaan|CTOR: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Volume dana dhuwit perusahaan|Fate Therapeutics, Inc. (FATE) - Aset likuid perusahaan|Dhuwit awis perusahaan WHWK (Aadi Bioscience, Inc.)|Aset likuid perusahaan TScan Therapeutics, Inc.|Volume dana dhuwit perusahaan CSBR (Champions Oncology Corp)|Gunggung dana dhuwit perusahaan XBIT (XBiotech USA)|CVM - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Dana dhuwit perusahaan|ARTV: Gunggung dana dhuwit perusahaan|ANL (adlainortye.com) - Volume dana dhuwit perusahaan|VERU: Sisa dhuwit perusahaan|Dhuwit awis perusahaan TPST (Tempest Tx)|Dhuwit awis perusahaan Xilio XLO|Volume dana dhuwit perusahaan RENB (Renovaro)|Volume dana dhuwit perusahaan Mural Bio MURA|Kairos Pharma Ltd - Volume dana dhuwit perusahaan|OnKure Therapeutics (OKUR) - Dhuwit awis perusahaan|GDTC: Volume dana dhuwit perusahaan|Curis Inc. - Sisa dhuwit perusahaan|Dana dhuwit perusahaan apollomicsinc.com|THAR: Sisa dhuwit perusahaan|Dana dhuwit perusahaan Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com (SBFM) - Cadangan dhuwit perusahaan|Xenetic Bio - Volume dana dhuwit perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan